Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Article

Benign prostatic hyperplasia: When to ‘watch and wait,’ when and how to treat

Matt T. Rosenberg, MD, Milton M. Lakin, MD, David R. Staskin, MD, Albert Levy, MD and George P. Samraj, MD
Cleveland Clinic Journal of Medicine May 2007, 74 (5 suppl 3) S15-S20;
Matt T. Rosenberg
Mid-Michigan Health Centers
Roles: Co-Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Milton M. Lakin
Cleveland Clinic
Roles: Co-Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Staskin
New York Presbyterian Hospital, Weill Medical College of Cornell University
Roles: Associate Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Levy
Assistant Clinical Professor of Medicine, Mount Sinai School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
George P. Samraj
Associate Professor, Family Medicine, Department of Community Health and Family Medicine, University Of Florida, Gainesville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Benign prostatic hyperplasia (BPH) is a clinical diagnosis. While BPH is a common cause of lower urinary tract symptoms (LUTS) in men, LUTS can signify a number of other disease states. For this reason, the patient evaluation, which includes a digital rectal examination, and careful differential diagnosis are crucial in men with LUTS. Many men with BPH are asymptomatic, and many others are not bothered by their symptoms; watchful waiting is appropriate management for these patients. When symptoms affect quality of life, pharmacologic therapy should be an option; choices include an alpha-blocker, a 5 alpha-reductase inhibitor, or, for men with larger prostates, a combination of the two. Surgical intervention is indicated when BPH leads to other medical complications, including urinary retention and renal insufficiency.

Footnotes

  • ↵* Milton M. Lakin, MD, has received consulting fees and honoraria from Pfizer and Eli Lilly/ICOS for consulting, teaching/speaking, and advisory board membership. He also reported having stock ownership interest in Pfizer and Eli Lilly.

  • ↵** David R. Staskin, MD, has received honoraria from ESPRIT Pharma, Novartis, Pfizer, Ortho-McNeil, Watson Pharmaceuticals, and Astellas Pharma for teaching/speaking.

  • ↵* Drs. Levy and Samraj reported that they have no financial relationships that pose a potential conflict of interest with this article.

  • Copyright © 2007 The Cleveland Clinic Foundation. All Rights Reserved.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 74 (5 suppl 3)
Cleveland Clinic Journal of Medicine
Vol. 74, Issue 5 suppl 3
1 May 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Benign prostatic hyperplasia: When to ‘watch and wait,’ when and how to treat
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Benign prostatic hyperplasia: When to ‘watch and wait,’ when and how to treat
Matt T. Rosenberg, Milton M. Lakin, David R. Staskin, Albert Levy, George P. Samraj
Cleveland Clinic Journal of Medicine May 2007, 74 (5 suppl 3) S15-S20;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Benign prostatic hyperplasia: When to ‘watch and wait,’ when and how to treat
Matt T. Rosenberg, Milton M. Lakin, David R. Staskin, Albert Levy, George P. Samraj
Cleveland Clinic Journal of Medicine May 2007, 74 (5 suppl 3) S15-S20;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • New treatments for peripheral artery disease
  • Functional tricuspid regurgitation: Feasibility of transcatheter interventions
  • A practical approach to the cholesterol guidelines and ASCVD prevention
Show more Article

Similar Articles

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire